DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.
Sign in and take the values quiz to see how this bill lines up with what you've said.
The INSULIN Act of 2026 reduces patient cost-sharing for insulin products covered by private health insurance plans and establishes programs to improve insulin affordability. The bill caps insulin copayments at $35 per 30-day supply through 2027, then limits cost-sharing to the lesser of $35 or 25 percent of the negotiated price thereafter, while prohibiting prior authorization requirements on selected insulin products. It also requires pharmacy benefit managers to pass through all rebates to plans, accelerates generic and biosimilar insulin competition, and establishes a pilot program and hotline to help uninsured individuals access affordable insulin.
Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.
Sign in to see how your representatives voted on this bill.